ASCO 2023 Melanoma & Skin Cancer Highlights with Prof Elizabeth Buchbinder

Free MedAll Certification - Fill in the 1 minute feedback form to get a certificate of learning for your CV:
app.medall.org/feedback/feedb...
Professor Buchbinder from the Dana-Farber Cancer Institute & Harvard Medical School talks to Dr Phil McElnay to summarize the latest advances and trials in Skin Cancer and Melanoma from ASCO 2023 (the annual meeting of the American Society of Clinical Oncology) including:
• Individualised therapy and mRNA vaccines
• Re-targeting with new drugs such as Relatlimab and Fianlimab
• Cellular therapy as an emerging therapy for melanoma
• The potential of neoadjuvant therapy
She also discusses advances she expects to see coming in the future, including targeted therapies and novel combinations of drugs before surgery to improve patient outcomes.
About Professor Buchbinder
Professor Buchbinder is based at the Dana-Farber Cancer Institute and is an assistant Professor at Harvard Medical School. She is a well respected clinical oncologist who specialises in melanoma. Her work focusses on early drug development and testing in melanoma, with an interest in novel immunotherapy and phase I trials, as well as refining melanoma therapies to improve patient outcomes and survivorship.
About MedAll
MedAll is the fastest growing community of medical professionals and students. Alongside thousands of incredible healthcare organisations and individuals from institutions like Harvard Medical School, Johns Hopkins & Baylor Medical School, we have built an amazing resource of free online medical teaching sessions, conferences and on demand videos that can be accessed anytime:
• Track your CME/CPD
• Learn from the best educators
• Build your CV with certificates of learning
• Prepare for exams, interviews & assessments
We are on a mission to help train millions more healthcare workers by increasing access to great training, reducing travel barriers, providing flexibility around parental or other caring responsibilities and by offering alternative ways to study to support neurodiversity.
Together, we have the power to make change, join us!

[@chrissilver6770]

Most amazing Doctor that I’ve ever had the pleasure of knowing